SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : TITAN PHARMACEUTICAL (TTP)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: BRAVEHEART who wrote (62)5/18/1999 9:14:00 AM
From: scaram(o)uche   of 362
 
this is what the company is reporting for TriGem.......

biz.yahoo.com

The Company reported that 40 of 47 patients generated strong, anti- cancer immune responses
following administration of TriGem. Preliminary clinical responses were encouraging, with a complete clinical response in one
patient, who remains without evidence of disease for a period of 18 months, and 17 additional patients with stable disease for
periods ranging from 10-36 months. The median survival has not been reached for the total patient population or for the 26
patients with soft tissue disease. For the 18 patients with visceral metastases, the median survival was 15 months.

''These survival results compare quite well to that seen in previously published reports with other drug regimens in these
patients,'' commented Dr. Ken Foon, Director of the Barrett Center for Prevention, Treatment and Research at the University
of Cincinnati, who presented this data at ASCO. ''TriGem appears to have a favorable positive impact on disease progression
and survival.''
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News